AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30999906 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol candies
Number of subjects: 90
Study 30999906 — intervention group
Group type: COMPARATOR
Intervention: Control (sorbitol) candies
Number of subjects: 90
Study 30999933 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg or 4 mg with or without concomitant methotrexate (MTX)
Number of subjects: 106
Study 30999993 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter tricuspid valve reconstruction system
Number of subjects: 30
Study 31000430 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI after 6 months of enzalutamide and goserelin (AA-ADT)
Number of subjects: 20
Study 31000430 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI T2 weighted sequences
Number of subjects: 20
Study 31000755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean section
Number of subjects: 0
Study 31000755 — intervention group
Group type: EXPERIMENTAL
Intervention: Islet autoimmunity
Number of subjects: 0
Study 31000755 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Cesarean section and islet autoimmunity
Number of subjects: 0
Study 31001350 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Moxibustion (CM)
Number of subjects: 138
Study 31001350 — intervention group
Group type: COMPARATOR
Intervention: Smoke-Free Moxibustion (SM)
Number of subjects: 138
Study 31001535 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (encouragement of balance and variety) at age 5
Number of subjects: 428
Study 31001535 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (pressure to eat) at age 5
Number of subjects: 428
Study 31001535 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (restriction) at age 5
Number of subjects: 428
Study 31001535 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal feeding practices (pressure) at age 5
Number of subjects: 428
Study 31001674 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes with normal awareness of hypoglycaemia (NAH)
Number of subjects: 44
Study 31001674 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes with impaired awareness of hypoglycaemia (IAH)
Number of subjects: 44
Study 31001674 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic control participants
Number of subjects: 44
Study 31003631 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective cognitive complaints (SCC) after surgery
Number of subjects: 120
Study 31003631 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective cognitive decline
Number of subjects: 120
Study 31003631 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity of SCC in relation to objective decline
Number of subjects: 120
Study 31003631 — intervention group
Group type: EXPERIMENTAL
Intervention: Specificity of SCC in relation to objective decline
Number of subjects: 120
Study 31003631 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC and depression screening
Number of subjects: 120
Study 31003789 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-fed group (those already receiving nutritional support)
Number of subjects: 342
Study 31003789 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher caloric intake (≥20 kcal/kg)
Number of subjects: 342
Study 31003789 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake (≥1.3 g of protein/kg)
Number of subjects: 342
Study 31003789 — intervention group
Group type: COMPARATOR
Intervention: Non-fed group (without nutritional support)
Number of subjects: 342
Study 31003789 — intervention group
Group type: COMPARATOR
Intervention: Caloric intake (<20 kcal/kg)
Number of subjects: 342
Study 31003789 — intervention group
Group type: COMPARATOR
Intervention: Protein intake (<1.3 g of protein/kg)
Number of subjects: 342
Study 31003871 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of pain in communicative patients (CP)
Number of subjects: 1574
Study 31003871 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of pain in non-communicative patients (NCP)
Number of subjects: 1574
Study 31003871 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of sedation/agitation
Number of subjects: 1574
Study 31003871 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of delirium
Number of subjects: 1574
Study 31003871 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of physical restraint (PR)
Number of subjects: 1574
Study 31003963 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab 6 mg/kg subcutaneously every 4 weeks for 24 weeks or more (with 4 loading doses of 3 mg/kg once weekly for the expansion cohort)
Number of subjects: 48
Study 31003963 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab 6 mg/kg subcutaneously every 4 weeks
Number of subjects: 48
Study 31003963 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab
Number of subjects: 48
Study 31004066 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OAs)
Number of subjects: 937
Study 31004066 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbleeds
Number of subjects: 937
Study 31004066 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe white matter hyperintensities
Number of subjects: 937
Study 31004066 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral small vessel disease
Number of subjects: 937
Study 31004273 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical velocimetry (EV)
Number of subjects: 32
Study 31004273 — intervention group
Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 32
Study 31004324 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg SC every 2 weeks + methotrexate
Number of subjects: 0
Study 31004324 — intervention group
Group type: COMPARATOR
Intervention: Active csDMARD
Number of subjects: 0
Study 31004324 — intervention group
Group type: COMPARATOR
Intervention: Etanercept + methotrexate
Number of subjects: 0
Study 31004324 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab + methotrexate
Number of subjects: 0
Study 31004324 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab, certolizumab, golimumab, tofacitinib + methotrexate
Number of subjects: 0
Study 31004405 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet for 8 weeks followed by 4 weeks of refeeding and a 1-year maintenance program
Number of subjects: 36
Study 31004405 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 36
Study 31004405 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in RMR, EIEE, or appetite following WL
Number of subjects: 36
Study 31004409 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF gene expression in human subcutaneous preadipocytes before and after inducing adipogenesis
Number of subjects: 72
Study 31004409 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue CTGF expression
Number of subjects: 72
Study 31004409 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive weight loss (5%, 11%, and 16%)
Number of subjects: 72
Study 31004409 — intervention group
Group type: EXPERIMENTAL
Intervention: CTGF-positive cells localization
Number of subjects: 72
Study 31004598 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic eradication therapy (EET) with complete eradication of intestinal metaplasia (CE-IM)
Number of subjects: 443
Study 31004788 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial progenitor cells (EPCs)
Number of subjects: 0
Study 31004788 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 31005312 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD
Number of subjects: 103
Study 31005312 — intervention group
Group type: COMPARATOR
Intervention: IVF/ICSI
Number of subjects: 103
Study 31005312 — intervention group
Group type: COMPARATOR
Intervention: NC
Number of subjects: 103
Study 31005537 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of multiple myocardial scars detected by CMR at 3 months post-STEMI.
Number of subjects: 704
Study 31005537 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of multiple myocardial scars detected by CMR.
Number of subjects: 704
Study 31005540 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR intervention
Number of subjects: 5083
Study 31005729 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide for 48 weeks
Number of subjects: 1000
Study 31005932 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP monitoring and ICP-driven therapy
Number of subjects: 0
Study 31005932 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination data (GCS, pupil size and reactivity, Richmond Agitation-Sedation Scale score, neuroimaging)
Number of subjects: 0
Study 31005932 — intervention group
Group type: EXPERIMENTAL
Intervention: GOSE
Number of subjects: 0
Study 31005944 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 22
Study 31006005 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting
Number of subjects: 192
Study 31006005 — intervention group
Group type: COMPARATOR
Intervention: Occluded anastomoses
Number of subjects: 192
Study 31006005 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful interventional revascularization
Number of subjects: 192
Study 31006809 — intervention group
Group type: EXPERIMENTAL
Intervention: Household Food Insecurity (HFI)
Number of subjects: 121
Study 31006809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol and hsCRP
Number of subjects: 121
Study 31006811 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (25 g/d)
Number of subjects: 46
Study 31006811 — intervention group
Group type: COMPARATOR
Intervention: Non-soy protein
Number of subjects: 46
Study 31006980 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV direct-acting antiviral (DAA) treatment
Number of subjects: 3075
Study 31006980 — intervention group
Group type: COMPARATOR
Intervention: Opioid substitutive therapy (OST-PWID)
Number of subjects: 3075
Study 31006980 — intervention group
Group type: COMPARATOR
Intervention: Recent people who inject drugs (recent PWID)
Number of subjects: 3075
Study 31007855 — intervention group
Group type: EXPERIMENTAL
Intervention: Gulf DYSPNEA registry
Number of subjects: 3500
Study 31008307 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised protocol examination and follow-up for 10 years
Number of subjects: 600
Study 31008307 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralised reading of echocardiography, electrocardiography, and neurovascular imaging
Number of subjects: 600
Study 31008307 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples for genetic, gene-expression, thrombosis and haemostasis and biomarker analysis
Number of subjects: 600
Study 31008307 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypic and genetic data analysis
Number of subjects: 600
Study 31008307 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems medicine approach to investigate complex risk-factor interactions
Number of subjects: 600
Study 31008354 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of spasticity
Number of subjects: 57
Study 31008354 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of cognition
Number of subjects: 57
Study 31008354 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of depression
Number of subjects: 57
Study 31008354 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of medication compliance
Number of subjects: 57
Study 31008509 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 2028
Study 31008636 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Tolerance Scale
Number of subjects: 263
Study 31008636 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Tracing Persistence Task
Number of subjects: 263
Study 31008636 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence duration
Number of subjects: 263
Study 31008636 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of use
Number of subjects: 263
Study 31009130 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1821
Study 31009235 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31009356 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation mechanical thrombectomy device (Embolus Retriever with Interlinked Cages/SOFIA, Microvention)
Number of subjects: 81
Study 31009356 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tPA therapy (IVT)
Number of subjects: 81
Study 31009701 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-grass tablet (sublingual immunotherapy), daily dosage with a 3-day dose escalation to 300 index of reactivity (IR) for 30 days
Number of subjects: 307
Study 31010300 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional mobility assessment
Number of subjects: 3006
Study 31010300 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model including functional mobility and other variables
Number of subjects: 3006
Study 31010300 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional mobility
Number of subjects: 3006
Study 31010300 — intervention group
Group type: EXPERIMENTAL
Intervention: Readmission within 30 days
Number of subjects: 3006
Study 31010300 — intervention group
Group type: COMPARATOR
Intervention: Activities of daily living disability
Number of subjects: 3006
Study 31010300 — intervention group
Group type: COMPARATOR
Intervention: Impaired functional mobility
Number of subjects: 3006
Study 31010434 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad5-GUCY2C-PADRE vaccine
Number of subjects: 10
Study 31010744 — intervention group
Group type: EXPERIMENTAL
Intervention: 25G fork-tip needle
Number of subjects: 100
Study 31010846 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Response (CR)
Number of subjects: 384
Study 31010846 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertain Complete Response (uCR)
Number of subjects: 384
Study 31010846 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Good Partial Response (VGPR)
Number of subjects: 384
Study 31010846 — intervention group
Group type: EXPERIMENTAL
Intervention: uIFE positive rate
Number of subjects: 384
Study 31011205 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA sequencing (arm A; 236 gene panel)
Number of subjects: 303
Study 31011205 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA expression (arm B; comparing tumor to normal)
Number of subjects: 303
Study 31011205 — intervention group
Group type: EXPERIMENTAL
Intervention: WINTHER therapy
Number of subjects: 303
Study 31011207 — intervention group
Group type: EXPERIMENTAL
Intervention: CD19-BBz(86) CAR T cell therapy, dose: 2 × 10^6 cells
Number of subjects: 11
Study 31011363 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen deficiency-FD group
Number of subjects: 276
Study 31011363 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 15 metabolites
Number of subjects: 276
Study 31011363 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 15 metabolites and motilin
Number of subjects: 276
Study 31011363 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased motilin
Number of subjects: 276
Study 31011363 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (HC)
Number of subjects: 276
Study 31011425 — intervention group
Group type: EXPERIMENTAL
Intervention: FloTrac™ algorithm with a fourth-generation algorithm
Number of subjects: 17
Study 31011425 — intervention group
Group type: COMPARATOR
Intervention: Critical care ultrasonography
Number of subjects: 17
Study 31012090 — intervention group
Group type: COMPARATOR
Intervention: Prop sitting
Number of subjects: 31
Study 31012090 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobbly/arms-free sitting
Number of subjects: 31
Study 31012090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting skill
Number of subjects: 31
Study 31012090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting stage and skill
Number of subjects: 31
Study 31012296 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein overfeeding diet
Number of subjects: 0
Study 31012296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 24 hours
Number of subjects: 0
Study 31012296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure (e.g., brown adipose tissue activation)
Number of subjects: 0
Study 31012356 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 206
Study 31012356 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life assessment using QLQ-C30 and EQ-5D
Number of subjects: 206
Study 31012861 — intervention group
Group type: EXPERIMENTAL
Intervention: H3 Tracker (Healthy Minds, Healthy Children, Healthy Chicago Tracker)
Number of subjects: 277
Study 31012861 — intervention group
Group type: EXPERIMENTAL
Intervention: Usability testing of the H3 Tracker
Number of subjects: 277
Study 31012861 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the H3 Tracker
Number of subjects: 277
Study 31012862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitted condoms
Number of subjects: 504
Study 31012862 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin condoms
Number of subjects: 504
Study 31012862 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard condoms
Number of subjects: 504
Study 31012862 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study condom preference
Number of subjects: 504
Study 31012962 — intervention group
Group type: EXPERIMENTAL
Intervention: CC-486 300 mg daily on days 1 through 14 and romidepsin 8 mg/m²
Number of subjects: 14
Study 31012962 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease control rate (DCR)
Number of subjects: 14
Study 31012967 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib with standard-dose induction and consolidation therapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) when possible.
Number of subjects: 125
Study 31012967 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in TKI for molecular disease recurrence.
Number of subjects: 125
Study 31012967 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue chemotherapy and TKI change followed by second allo-HSCT for overt disease recurrence.
Number of subjects: 125
Study 31013390 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2038 weekly (8, 16, 24 or 32 mg) or monthly (64, 96, 128 or 160 mg)
Number of subjects: 228
Study 31013390 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM2038 weekly or monthly
Number of subjects: 228
Study 31014072 — intervention group
Group type: EXPERIMENTAL
Intervention: Firibastat (250 mg BID for 2 weeks, then 500 mg BID if AOBP >140/90 mm Hg; hydrochlorothiazide 25 mg QD added after 1 month if AOBP ≥160/110 mm Hg)
Number of subjects: 256
Study 31014072 — intervention group
Group type: EXPERIMENTAL
Intervention: Firibastat alone (85% of subjects)
Number of subjects: 256
Study 31014072 — intervention group
Group type: EXPERIMENTAL
Intervention: Firibastat
Number of subjects: 256
Study 31014291 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot length measurement (cut-off ≤7.7 cm)
Number of subjects: 376
Study 31014291 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest circumference measurement (cut-off ≤31.6 cm)
Number of subjects: 376
Study 31014291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid upper arm circumference (MUAC) measurement (cut-off ≤10.1 cm)
Number of subjects: 376
Study 31014330 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of T2DM > 10.5 years
Number of subjects: 259
Study 31014330 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) > 140 mm Hg
Number of subjects: 259
Study 31014330 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of T2DM > 10.5 years and SBP > 140 mm Hg
Number of subjects: 259
Study 31014330 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) score
Number of subjects: 259
Study 31014330 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence and number of coronary artery plaques
Number of subjects: 259
Study 31014330 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant plaque (defined as > 50% luminal stenosis)
Number of subjects: 259
Study 31014330 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (SBP) borderline significance
Number of subjects: 259
Study 31014358 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text message intervention (0-3 messages per day, 113 messages for female-not married and 120 messages for female-married) for 120 days
Number of subjects: 578
Study 31014358 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone text message intervention
Number of subjects: 578
Study 31014358 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 messages over 120 days about trial participation)
Number of subjects: 578
Study 31014395 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated CLL patients
Number of subjects: 0
Study 31014683 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic Atrophy (GA)
Number of subjects: 68
Study 31014683 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Geographic Atrophy (NGA)
Number of subjects: 68
Study 31014683 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Fibrotic Scar (NFS)
Number of subjects: 68
Study 31014683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrotic Scar (FS)
Number of subjects: 68
Study 31014695 — intervention group
Group type: EXPERIMENTAL
Intervention: M3R involved in the atrophic process
Number of subjects: 31
Study 31014695 — intervention group
Group type: EXPERIMENTAL
Intervention: M3R nonatrophic
Number of subjects: 31
Study 31015207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic oral NAC
Number of subjects: 103
Study 31015207 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 103
Study 31015344 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput screening of tumor- and neoantigen-specific CD4 T cells
Number of subjects: 2
Study 31015389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous triiodothyronine (0.4 μg/kg bolus followed by 0.6 μg/kg continuous perfusion for 24 h)
Number of subjects: 15
Study 31016030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) using a treat and extend (TAE) dosing regimen.
Number of subjects: 20
Study 31016233 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy in the NBRST study (NCT01479101) for ER-positive HER2-negative breast cancers.
Number of subjects: 694